Table S1.
Study month | Annualized exacerbation rates
|
|||
---|---|---|---|---|
All patients, n=2,345
| ||||
BUD/FOR | 95% CI | FOR | 95% CI | |
1 | 0.60 | 0.48–0.84 | 1.20 | 0.96–1.44 |
2 | 0.60 | 0.54–0.72 | 1.20 | 1.02–1.32 |
3 | 0.60 | 0.52–0.72 | 1.12 | 1.0–1.24 |
4 | 0.60 | 0.54–0.69 | 1.11 | 0.99–1.23 |
5 | 0.62 | 0.58–0.72 | 1.06 | 0.98–1.17 |
6 | 0.66 | 0.60–0.74 | 1.04 | 0.96–1.14 |
7 | 0.67 | 0.62–0.74 | 0.99 | 0.99–1.06 |
8 | 0.68 | 0.62–0.74 | 0.95 | 0.87–1.02 |
9 | 0.68 | 0.63–0.74 | 0.93 | 0.93–1.01 |
10 | 0.66 | 0.61–0.72 | 0.94 | 0.86–.996 |
11 | 0.65 | 0.61–0.72 | 0.91 | 0.85–0.98 |
12 | 0.63 | 0.58–0.68 | 0.86 | 0.80–0.92 |
Abbreviations: BUD, budesonide; CI, confidential interval; FOR, formoterol.